Maximum Selling Prices in the Colombian Pharmaceutical Market: An Impact Evaluation
By David Bardey & Arturo Harker (Universidad de los Andes), Daniela Zuluaga (Inter-American Development Bank)
We evaluate the impact of a maximum sellin price regulation implemented in the Colombian pharmaceutical market between 2011 and 2014. Our empirical approach takes advantage of a unique dataset where we observe three sources of variation: i) differences across 18 groups in the Anatomical Therapeutic Chemical (ATC) classification system of the WHO, ii) the existence of regulated (treated) and unregulated (control) groups within each of this 18 ATC groups, and iii) differences in time (before and afte rregulation) for the 18 ATC groups. A triple differences model with fixed time effects and cluster errors is used to identify the impact. We find that the regulation of price ceilings to reduced prices in 3 of the 18 groups and increased the price in 10 of them. We confirm then that the focal point effect of price ceilings can distort this type of regulation. In the case studied, the regulation of price ceilings has contributed to an increase in drug expenses by 30% for the 18 ATC groups considered.
Download Full Article: HERE
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan